Black Diamond Therapeutics (BDTX) Revenue (2025)

Black Diamond Therapeutics (BDTX) posted Revenue of $70.0 million for Q1 2025.

Black Diamond Therapeutics (BDTX) Revenue (2025) Analysis & Trends

Black Diamond Therapeutics' Revenue history runs 1 years deep, the most recent figure standing at $70.0 million for Q1 2025.

  • Quarterly Revenue changed N/A year-over-year to $70.0 million in Q1 2025, while the trailing twelve-month figure through Dec 2025 was $70.0 million (changed N/A YoY) and the FY2025 annual result came in at $70.0 million, changed N/A from the prior year.
  • Revenue was $70.0 million for Q1 2025 at Black Diamond Therapeutics.
  • Across five years, Revenue topped out at $70.0 million in Q1 2025 and bottomed at $70.0 million in Q1 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Revenue (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 1.51 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 2.99 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn 3.61 Bn
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 1.56 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Black Diamond Therapeutics 99.59 Mn -18.67 Mn - -

Historic Data

Download Data
DateValue
Mar 31, 2025 70.00 Mn